C R Bard Inc (BCR) : Davis R M Inc scooped up 805 additional shares in C R Bard Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 18, 2016. The investment management firm now holds a total of 192,157 shares of C R Bard Inc which is valued at $39,820,695.C R Bard Inc makes up approximately 1.99% of Davis R M Inc’s portfolio.
C R Bard Inc opened for trading at $207.53 and hit $208.84 on the upside on Friday, eventually ending the session at $207.23, with a gain of 0.10% or 0.21 points. The heightened volatility saw the trading volume jump to 4,02,988 shares. Company has a market cap of $15,280 M.
Other Hedge Funds, Including , Tnb Financial added BCR to its portfolio by purchasing 3,350 company shares during the most recent quarter which is valued at $692,747. C R Bard Inc makes up approx 0.21% of Tnb Financial’s portfolio.Palisade Asset Management reduced its stake in BCR by selling 25 shares or 0.49% in the most recent quarter. The Hedge Fund company now holds 5,115 shares of BCR which is valued at $1,057,731. C R Bard Inc makes up approx 0.21% of Palisade Asset Management’s portfolio. Santa Fe Partners sold out all of its stake in BCR during the most recent quarter. The investment firm sold 19,792 shares of BCR which is valued $4,092,788.
On the company’s financial health, C R Bard Inc reported $2.43 EPS for the quarter, beating the analyst consensus estimate by $ 0.26 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $2.17. The company had revenue of $870.80 million for the quarter, compared to analysts expectations of $867.23 million. The company’s revenue was up .4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.29 EPS.
Many Wall Street Analysts have commented on C R Bard Inc. C R Bard Inc was Initiated by Nomura to “Neutral” on Mar 17, 2016.
C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.